Involved in the acquisition of Bluerock Therapeutics by Bayer in 2019, as Investment Director at Leaps, Alasdair Thong is a Venture Partner in several international VC funds. Given his strong
Involved in the acquitision of Bluerock Therapeutics by Bayer in 2019, as Investment Director, Alasdair Thong is a Venture Partner with a strong expertise in iPS-derived cell therapies. We asked
Involved in the acquisition of Bluerock Therapeutics by Bayer in 2019, as Investment Director at Leaps, Alasdair Thong is a Venture Partner in several international VC funds. Given its specific
Albert Hwa, Operations Director at the Joslin’s Center for Cell-Based Therapy for Diabetes (CCTD) and Lecturer the Harvard Medical School, discusses the view according to which transplanting too much beta
Albert Hwa, Operations Director at the Joslin’s Center for Cell-Based Therapy for Diabetes (CCTD) and Lecturer the Harvard Medical School, gives a quick overview of the limitations of pancreatic progenitor
Albert Hwa, Operations Director at the Joslin’s Center for Cell-Based Therapy for Diabetes (CCTD) and Lecturer the Harvard Medical School, explains the rationale behind cell therapies for diabetes, and the
Albert Hwa, Operations Director at the Joslin’s Center for Cell-Based Therapy for Diabetes (CCTD) and Lecturer the Harvard Medical School, discusses the pro and cons of shielding stem-cell derived β-Cells
Albert Hwa explains why the Joslin’s CCTD launched an autologous cell therapy program, and discusses the promise of allogeneic cell therapies for Diabetes.
Albert Hwa, Operations Director at the Joslin’s Center for Cell-Based Therapy for Diabetes (CCTD), provides an overview of the cell therapy initiatives and current trials in the field of Diabetes,
Laurence Daheron, Phd, Head of the iPS Core Facility at the Harvard Stem Cell Institute, discusses the benefits of hypoxic conditions in iPS facilities.
Laurence Daheron, Phd, Head of the iPS Core Facility at the Harvard Stem Cell Institute, discusses autologous iPS and HLA-matched embryonic stem cells.
Laurence Daheron, Phd, Head of the iPS Core Facility at the Harvard Stem Cell Institute, on the organoid format for next generation cell therapies.
The webcast In the Stem Cell Jungle becomes a blog about pluripotent stem cells and their applications in cell therapy. Maxime Feyeux, CSO of TreeFrog, who was hosting the webcast on youtube, is now editor of the blog, which brings together developmental biology insights about pluripotent stem cells (both iPS & ES cells) and views from the industry about iPS-derived cell therapies for regenerative medicine and immune-oncology. The blog is also featuring free access resources, such as a whitebook about the epiblast rosette and how to leverage this in vivo structure to manufacture iPSCs at scale using biomimetic technologies such as C-Stem, as well as a list of cell therapy programs based on pluripotent stem cells in clinical trial.